INMB News and Press, INmune Bio Inc. From 11/15/23

The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive . Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology co...

2023-11-01 22:38:08 ET INmune Bio, Inc. (INMB) Q3 2023 Earnings Conference Call November 01, 2023 04:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call...

2023-11-01 16:57:03 ET More on INmune Bio Capitalizing On Inflammation's Role In Neurological Disease Part 2: INmune Bio INmune Bio: Some Promise, But Take Care Here INmune Bio, Inc. (INMB) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating ...

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

INmune Bio Inc. (INMB) is expected to report for Q1 2024

INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune ...

SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP) . Boca Raton, Florida, Oct. 30, 2023 (...

2023-10-26 09:49:41 ET Summary INmune Bio is a phase 2 stage biotech company focusing on Alzheimer's and other diseases with its lead asset, XPro, and its endogenous NK cell activator, INKmune. INmune's XPro has shown promising results in stabilizing Alzheimer's disease and improv...

An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most affected regions of the AD brain; an effect that was accompanied by an improvement in neuronal proteins and EEG changes associated with cor...